Sign in
Enrolling by invitationPhase 3

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

Key facts

Who runs it
JCR Pharmaceuticals Co., Ltd.
Where
Oakland and Philadelphia, United StatesSee the 2 sitesAlso in 7 other countries, 16 sites
Status
Enrolling by invitation
Phase
Phase 3
People taking part
80 people, planned
Started
22 Feb 2023
Expected to end
28 Feb 2028
Type of study
Interventional
Treatments tested
  • JR-141
Record updated
21 January 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • A subject who participated in the Parent Study (JR-141-GS31) and completed the assessments at Week 105 in Cohort A or Week 53 in Cohort B before being administered the study medication of that respective visit, and in the opinion of the principal investigator there are no safety concerns
  • A subject from whom an IRB or IEC-approved written informed consent can be obtained, which is voluntarily signed. If the subject is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the subject's legally acceptable representative (e.g., his parents or guardians) may sign the ICF on behalf of the subject. Written informed assent should be obtained from the subject, wherever possible
  • Female subject of child bearing potential or male subject whose female partner is of child-bearing potential, i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile, agrees to use a medically accepted, highly effective method of contraception from the time of signing the ICF. The method of contraception must be used during the study until 90 days for male subjects, and 30 days for female subjects after the final study drug administration

Who cannot take part

  • A subject who changed treatment from JR-141 to idursulfase during the treatment period in the Parent Study (JR-141-GS31)
  • A subject who is unable to comply with the protocol (e.g., is unable to return for safety evaluations or is otherwise unlikely to complete the study) as determined by the principal investigator or sub-investigator
  • [Only in France] Persons deprived of their liberty by a judicial or administrative decision, according to article L. 1121-6 of the Public Health Code (Code de la santé publique, CSP) adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the CSP

Where in United States

Also in 7 other countries, 16 sites

  • UCSF Benioff Children's Hospital OaklandOakland, United StatesEnrolling by invitation
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

An extension of Global Phase III open-label, multicenter designed to evaluate the Long-term safety and efficacy of study drug for the treatment of the MPS II.

The group in the trial

  • JR-141 2.0 mg/kg/weekTreatment being tested

    Treatment: JR-141

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
Record updated
21 January 2026